181 related articles for article (PubMed ID: 1497422)
1. [Treatment of adenosine deaminase deficiency with adenosine deaminase combined with polyethylene glycol].
Girault D; Le Deist F; Debré M; Pérignon JL; Herbelin C; Griscelli C; Sciudery D; Hershfield M; Fischer A
Arch Fr Pediatr; 1992 Apr; 49(4):339-43. PubMed ID: 1497422
[TBL] [Abstract][Full Text] [Related]
2. Burkitt's lymphoma in a patient with adenosine deaminase deficiency-severe combined immunodeficiency treated with polyethylene glycol-adenosine deaminase.
Husain M; Grunebaum E; Naqvi A; Atkinson A; Ngan BY; Aiuti A; Roifman CM
J Pediatr; 2007 Jul; 151(1):93-5. PubMed ID: 17586199
[TBL] [Abstract][Full Text] [Related]
3. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years.
Hershfield MS
Clin Immunol Immunopathol; 1995 Sep; 76(3 Pt 2):S228-32. PubMed ID: 7554473
[TBL] [Abstract][Full Text] [Related]
4. PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency.
Hershfield MS
Hum Mutat; 1995; 5(2):107-12. PubMed ID: 7749407
[TBL] [Abstract][Full Text] [Related]
5. Suppression of an antibody to adenosine-deaminase (ADA) in an ADA-deficient patient receiving polyethylene glycol modified adenosine deaminase.
Chun JD; Lee N; Kobayashi RH; Chaffee S; Hershfield MS; Stiehm ER
Ann Allergy; 1993 Jun; 70(6):462-6. PubMed ID: 8507039
[TBL] [Abstract][Full Text] [Related]
6. T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase.
Weinberg K; Hershfield MS; Bastian J; Kohn D; Sender L; Parkman R; Lenarsky C
J Clin Invest; 1993 Aug; 92(2):596-602. PubMed ID: 8349799
[TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement therapy of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase (PEG-ADA).
Hershfield MS
Immunodeficiency; 1993; 4(1-4):93-7. PubMed ID: 8167743
[No Abstract] [Full Text] [Related]
8. [Polyethylene glycol-adenosine deaminase: a new adenosine deaminase deficiency therapy. Value of deoxyadenosine triphosphate determination for therapeutic monitoring].
Bory C; Boulieu R; Souillet G; Hershfield MS
Therapie; 1991; 46(4):323-6. PubMed ID: 1948809
[TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement therapy with polyethylene glycol-adenosine deaminase in adenosine deaminase deficiency: overview and case reports of three patients, including two now receiving gene therapy.
Hershfield MS; Chaffee S; Sorensen RU
Pediatr Res; 1993 Jan; 33(1 Suppl):S42-7; discussion S47-8. PubMed ID: 8433874
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).
Chan B; Wara D; Bastian J; Hershfield MS; Bohnsack J; Azen CG; Parkman R; Weinberg K; Kohn DB
Clin Immunol; 2005 Nov; 117(2):133-43. PubMed ID: 16112907
[TBL] [Abstract][Full Text] [Related]
11. Cerebral lymphoma in an adenosine deaminase-deficient patient with severe combined immunodeficiency receiving polyethylene glycol-conjugated adenosine deaminase.
Kaufman DA; Hershfield MS; Bocchini JA; Moissidis IJ; Jeroudi M; Bahna SL
Pediatrics; 2005 Dec; 116(6):e876-9. PubMed ID: 16263974
[TBL] [Abstract][Full Text] [Related]
12. A 24-Year Enzyme Replacement Therapy in an Adenosine-deaminase-Deficient Patient.
Tartibi HM; Hershfield MS; Bahna SL
Pediatrics; 2016 Jan; 137(1):. PubMed ID: 26684479
[TBL] [Abstract][Full Text] [Related]
13. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency.
Chaffee S; Mary A; Stiehm ER; Girault D; Fischer A; Hershfield MS
J Clin Invest; 1992 May; 89(5):1643-51. PubMed ID: 1569204
[TBL] [Abstract][Full Text] [Related]
14. A 9-yr evaluation of carrier erythrocyte encapsulated adenosine deaminase (ADA) therapy in a patient with adult-type ADA deficiency.
Bax BE; Bain MD; Fairbanks LD; Webster AD; Ind PW; Hershfield MS; Chalmers RA
Eur J Haematol; 2007 Oct; 79(4):338-48. PubMed ID: 17680812
[TBL] [Abstract][Full Text] [Related]
15. Chondroosseous dysplasia in severe combined immunodeficiency due to adenosine deaminase deficiency (chondroosseous dysplasia in ADA deficiency SCID).
Chakravarti VS; Borns P; Lobell J; Douglas SD
Pediatr Radiol; 1991; 21(6):447-8. PubMed ID: 1749685
[TBL] [Abstract][Full Text] [Related]
16. Effect of polyethylene glycol-modified adenosine deaminase (PEG-ADA) therapy in two ADA-deficient children: measurement of erythrocyte deoxyadenosine triphosphate as a useful tool.
Bory C; Boulieu R; Souillet G; Chantin C; Guibaud P; Hershfield MS
Adv Exp Med Biol; 1991; 309A():173-6. PubMed ID: 1789201
[No Abstract] [Full Text] [Related]
17. Development of gene therapy for immunodeficiency: adenosine deaminase deficiency.
Blaese RM
Pediatr Res; 1993 Jan; 33(1 Suppl):S49-53; discussion S53-5. PubMed ID: 8433875
[TBL] [Abstract][Full Text] [Related]
18. Management options: SCIDS with adenosine deaminase deficiency.
Hilman BC; Sorensen RU
Ann Allergy; 1994 May; 72(5):395-403; quiz 403-4, 407. PubMed ID: 8179225
[TBL] [Abstract][Full Text] [Related]
19. Pegademase bovine: replacement therapy for severe combined immunodeficiency disease.
Lee CR; McKenzie CA; Webster KD; Whaley R
DICP; 1991 Oct; 25(10):1092-5. PubMed ID: 1803799
[TBL] [Abstract][Full Text] [Related]
20. Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome.
Nikolajeva O; Worth A; Hague R; Martinez-Alier N; Smart J; Adams S; Davies EG; Gaspar HB
J Clin Immunol; 2015 May; 35(4):366-72. PubMed ID: 25875700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
